Gene · 6240
RRM1: ribonucleotide reductase catalytic subunit M1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RRM1: ribonucleotide reductase catalytic subunit M1. Genes, record 6240. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6240
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P23921 | Ribonucleoside-diphosphate reductase large subunit | 792 | 12 | Ensembl, GeneID, HGNC |
Source UniProt
Patents42
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 61933 | P23921 | Espacenet |
| US 12208133 B2 | 2025-01-28 | 2 | P23921 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73864 | P23921 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 176835 | P23921 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 9823 | P23921 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 242368 | P23921 | Espacenet |
| JP 2018138044 A | 2018-09-06 | 145 | P23921 | Espacenet |
| US 10046010 B2 | 2018-08-14 | 145 | P23921 | Espacenet |
| EP 3258268 A1 | 2017-12-20 | 193 | P23921 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 242368 | P23921 | Espacenet |
1 to 10 of 42
See all 42 patentsDrugs10
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| CLOFARABINE | CHEMBL1750 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| FLUDARABINE PHOSPHATE | CHEMBL1096882 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| GALLIUM NITRATE | CHEMBL1200983 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE | CHEMBL888 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE HYDROCHLORIDE | CHEMBL1637 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| HYDROXYUREA | CHEMBL467 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| MOTEXAFIN GADOLINIUM | CHEMBL3544910 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| TEZACITABINE | CHEMBL3989496 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| TEZACITABINE ANHYDROUS | CHEMBL2105467 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| TRIAPINE | CHEMBL231616 | Ribonucleotide reductase inhibitor | INHIBITOR | ChEMBL |
Trials3,175
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | GEMCITABINE | PHASE3 | ClinicalTrials.gov | |
| NCT07603557 | FLUDARABINE PHOSPHATE | PHASE2 | ClinicalTrials.gov | |
| NCT07602140 | GEMCITABINE | PHASE2 | ClinicalTrials.gov | |
| NCT07598318 | GEMCITABINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07579195 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07575191 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07570849 | GEMCITABINE | PHASE2 | ClinicalTrials.gov | |
| NCT07570823 | GEMCITABINE | PHASE3 | ClinicalTrials.gov | |
| NCT07570017 | GEMCITABINE | PHASE1 | ClinicalTrials.gov | |
| NCT07569679 | GEMCITABINE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 3,175
See all 3,175 trialsNIH grants1,758
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RRM1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 22 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 13 | 2025 |
| P01CA013106 | Targeting Transcription and Splicing in Cancer | 11 | 2025 |
| P30CA022453 | CANCER CENTER SUPPORT GRANT | 11 | 2025 |
| P30CA033572 | Cancer Center Support Grant | 10 | 2025 |
| R01GM070503 | Molecular Recognition During Pre-mRNA Splicing | 10 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 9 | 2025 |
| ZIAAG000511 | Post-transcriptional control of Proliferation, Stress Response & Carcinogenesis | 8 | 2025 |
| P30CA043703 | Case Comprehensive Cancer Center Support Grant | 7 | 2025 |
| P30CA093373 | Cancer Center Support Grant P30 | 6 | 2025 |
1 to 10 of 1,758Source NIH's project files
See all 1,758 nih grantsPapers3,003
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Conformational plasticity and sequence specificity interplay in noncanonical tandem RRM-RNA binding. | Biophys J | 2026 | 42740374 | PubTator, text mining | PubMed |
| Astrocyte-microglia lactate shuttle restrains microglial phenotypic transition during myelin phagocytosis in radiation-induced brain injury. | Neurooncol Adv | 2026 | 42699581 | PubTator, text mining | PubMed |
| Ribonucleotide Reductase Inhibition Triggers Ferroptosis in Genetically Defined Subsets of Non-Small Cell Lung Cancer. | Cancer Res Commun | 2026 | 42664521 | PubTator, text mining | PubMed |
| A prognostic lncRNA signature associated with ribonucleotide reductase predicts overall survival and immune landscape in hepatocellular carcinoma. | Front Cell Dev Biol | 2026 | 42661875 | PubTator, text mining | PubMed |
| EF-P-Mediated Enhancement of Protein Synthesis: Cyclic Dipeptide Incorporation Using Mono- and Bisaminoacylated tRNAs. | ACS Chem Biol | 2026 | 42617067 | PubTator, text mining | PubMed |
| Molecular Docking and Pharmacological In Silico Evaluation of Genistein and Hematoxylin as Promising Ribonucleotide Reductase-targeted Therapies for Cancer. | Curr Comput Aided Drug Des | 2026 | 42576557 | PubTator, text mining | PubMed |
| Ensemble Docking and Molecular Dynamics Indicate Dynamic Modulation of hnRNPA1 UP1 Interdomain Behavior by Natural Products. | ACS Omega | 2026 | 42495344 | PubTator, text mining | PubMed |
| 3D epigenomic remodelling mediated by Foxa1 drives gemcitabine resistance in pancreatic cancer. | Cancer Lett | 2026 | 42457018 | PubTator, text mining | PubMed |
| Metabolic and Molecular Mechanisms of Gemcitabine Resistance in Urothelial Carcinoma. | Cancers (Basel) | 2026 | 42449668 | PubTator, text mining | PubMed |
| Chk1 inhibition emerges as the most effective partner for PARP inhibition in BRCA-proficient pancreatic cancer. | Discov Oncol | 2026 | 42446852 | PubTator, text mining | PubMed |
1 to 10 of 3,003
See all 3,003 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6240
GET https://conductscience.org/api/genes/v1/6240/patents?page=2